Lupin Partners With SteinCares To Supply Biosimilar in LATAM
ECONOMY & POLICY

Lupin Partners With SteinCares To Supply Biosimilar in LATAM

Global pharmaceutical major Lupin Limited has entered into a licence and supply agreement with SteinCares, a leading Latin American speciality healthcare firm, for the commercialisation of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.

As per the agreement, SteinCares will manage all regulatory submissions, registrations, and commercial activities, while Lupin will be responsible for manufacturing the biosimilar.

Ranibizumab is a recombinant humanised monoclonal antibody fragment (IgG1) that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat several retinal conditions including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularisation (mCNV).

Dr Cyrus Karkaria, President of Biotechnology at Lupin, said, “This partnership underscores our commitment to making advanced retinal therapies accessible in Latin America and improving patients’ quality of life.”

Sebastián Katz, Chief Strategy Officer at SteinCares, added, “Our collaboration with Lupin bolsters our leadership in the biosimilar space and helps bring affordable, high-quality treatments to healthcare systems across the region.”

This partnership aims to enhance the reach of cost-effective, advanced ophthalmic treatments across Latin America, aligning with both companies’ missions to deliver impactful healthcare solutions.

Global pharmaceutical major Lupin Limited has entered into a licence and supply agreement with SteinCares, a leading Latin American speciality healthcare firm, for the commercialisation of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.As per the agreement, SteinCares will manage all regulatory submissions, registrations, and commercial activities, while Lupin will be responsible for manufacturing the biosimilar.Ranibizumab is a recombinant humanised monoclonal antibody fragment (IgG1) that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat several retinal conditions including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularisation (mCNV).Dr Cyrus Karkaria, President of Biotechnology at Lupin, said, “This partnership underscores our commitment to making advanced retinal therapies accessible in Latin America and improving patients’ quality of life.”Sebastián Katz, Chief Strategy Officer at SteinCares, added, “Our collaboration with Lupin bolsters our leadership in the biosimilar space and helps bring affordable, high-quality treatments to healthcare systems across the region.”This partnership aims to enhance the reach of cost-effective, advanced ophthalmic treatments across Latin America, aligning with both companies’ missions to deliver impactful healthcare solutions.

Next Story
Infrastructure Urban

LANXESS Resin Removes Short-Chain PFAS From Water

Speciality chemicals company LANXESS has launched Lewatit MDS TP 108, a new ion exchange resin designed for the efficient removal of short-chain per- and polyfluoroalkyl substances (PFAS) from water. These PFAS compounds—characterised by having three or fewer carbon atoms—are among the smallest and most challenging to eliminate through conventional water purification methods.Lewatit MDS TP 108 marks a significant advancement in the treatment of contaminated water, particularly where traditional technologies such as activated carbon adsorption fall short. The new resin offers a service life..

Next Story
Technology

Fujifilm Unveils LTO-10 Tape With 75TB Storage

FUJIFILM India, a wholly owned subsidiary of FUJIFILM Holdings Corporation, Tokyo, has launched the “FUJIFILM LTO Ultrium 10 Data Cartridge” (LTO-10), a magnetic data storage solution offering a maximum recording capacity of 75 terabytes (30 terabytes uncompressed) per cartridge. This product is designed to provide secure, long-term, and cost-effective data storage for enterprises facing rising volumes of critical information.Commenting on the launch, Mr Koji Wada, Managing Director, FUJIFILM India, stated, “At FUJIFILM India, we are committed to delivering innovative products that embod..

Next Story
Infrastructure Urban

India’s Largest Multi Modal Cargo Terminal Opens at Manesar

India’s largest multi-modal cargo terminal under the Gati Shakti initiative has been unveiled in Manesar, Haryana. This state-of-the-art facility integrates rail and road logistics to streamline freight movement and significantly reduce transportation hassles for businesses across the region.The terminal features expansive storage yards, modern handling equipment for containers, and seamless connectivity to major highways and rail lines. It is designed to cater to a wide range of commodities—from bulk goods to manufactured products—supporting both road and rail operators through centrali..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?